[ACUR] Acura Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.78 Change: 0.04 (5.39%)
Ext. hours: Change: 0 (0%)

chart ACUR

Refresh chart

Strongest Trends Summary For ACUR

ACUR is in the long-term down -66% in 1 year and down -99% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company?s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. w

Fundamental Ratios
Shares Outstanding EPS-0.83 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 15205.7% Sales Growth - Q/Q912.67% P/E-0.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.11% ROE-120.96% ROI
Current Ratio3.98 Quick Ratio3.9 Long Term Debt/Equity0.66 Debt Ratio0.58
Gross Margin91.54% Operating Margin-113.11% Net Profit Margin-129.94% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities880 K Cash From Operating Activities2.17 M Gross Profit5.03 M
Net Profit1.24 M Operating Profit1.51 M Total Assets17.87 M Total Current Assets14.96 M
Total Current Liabilities3.76 M Total Debt9.72 M Total Liabilities11.35 M Total Revenue5.36 M
Technical Data
High 52 week0.84 Low 52 week0.1 Last close0.16 Last change-0.62%
RSI26.57 Average true range0.02 Beta0.61 Volume100.54 K
Simple moving average 20 days-25.47% Simple moving average 50 days-26.02% Simple moving average 200 days-58.59%
Performance Data
Performance Week-20% Performance Month-45.39% Performance Quart-20.04% Performance Half-64.91%
Performance Year-63.64% Performance Year-to-date-60.39% Volatility daily10.12% Volatility weekly22.63%
Volatility monthly46.37% Volatility yearly160.62% Relative Volume83.17% Average Volume14.41 K
New High New Low

News

2018-11-27 16:15:00 | Acura Pharmaceuticals Announces Third Quarter 2018 Financial Results

2018-10-09 16:15:00 | Acura Pharmaceuticals, Inc. Restructures Debt Obligations

2018-08-14 16:15:00 | Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results

2018-06-29 16:10:00 | Acura Pharmaceuticals Announces First Quarter 2018 Financial Results

2018-06-07 16:15:00 | Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results

2018-01-08 06:00:00 | Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301

2017-12-25 09:34:43 | Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

2017-11-13 16:15:00 | Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results

2017-10-09 06:15:00 | Acura Pharmaceuticals Advances LTX-03 and its LIMITx™ Technology

2017-09-11 06:30:00 | Acura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference

2017-09-07 12:00:40 | ETFs with exposure to Acura Pharmaceuticals, Inc. : September 7, 2017

2017-09-05 14:24:27 | Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017

2017-08-31 06:00:00 | Acura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference

2017-08-15 18:16:04 | Edited Transcript of ACUR earnings conference call or presentation 15-Aug-17 12:30pm GMT

2017-08-15 07:20:00 | Investor Network: Acura Pharmaceuticals, Inc. to Host Earnings Call

2017-08-14 16:15:00 | Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results

2017-08-03 06:00:00 | Acura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017

2017-07-24 16:43:16 | Acura Pharmaceuticals Raises $4.0 Million in a Private Placement

2017-06-28 16:10:00 | Acura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology

2017-05-24 10:14:00 | Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

2017-05-18 16:10:00 | Acura Pharmaceutical Initiates Second Clinical Study on LTX-04

2017-05-12 16:15:00 | Acura Pharmaceuticals Announces First Quarter 2017 Financial Results

2017-04-05 16:14:12 | ETFs with exposure to Acura Pharmaceuticals, Inc. : April 5, 2017

2017-04-04 08:57:43 | Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017

2017-04-03 19:36:12 | Edited Transcript of ACUR earnings conference call or presentation 3-Apr-17 12:30pm GMT

2017-03-31 16:17:08 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an

2017-03-31 16:05:24 | ACURA PHARMACEUTICALS, INC Files SEC form 10-K, Annual Report

2017-03-31 16:01:00 | Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results

2017-03-17 06:31:14 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan

2017-03-17 06:15:00 | Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products

2017-02-24 16:37:41 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers

2017-02-15 16:27:21 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

2017-02-15 16:15:00 | Acura Pharmaceuticals Common Stock To Trade On The OTCQB Market

2017-01-27 16:31:58 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

2017-01-03 17:05:15 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events

2017-01-03 16:23:29 | Acura Pharmaceuticals Exploring Strategic Alternatives

2017-01-03 16:15:00 | Acura Pharmaceuticals Exploring Strategic Alternatives

2016-12-23 12:24:45 | ETFs with exposure to Acura Pharmaceuticals, Inc. : December 23, 2016

2016-12-14 16:26:00 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events

2016-12-14 16:19:00 | 4:19 pm Acura Pharma announces the FDA has provided it with advice on the continued development of LTX-04; co intends to advance new formulations of LTX-04 tablets to a second pharmacokinetic study which is expected to start in late first q

2016-12-14 16:15:00 | Acura Pharmaceutical Provides Development Update on its LIMITxTM Technology

2016-12-07 11:22:11 | ETFs with exposure to Acura Pharmaceuticals, Inc. : December 7, 2016

2016-11-18 11:27:30 | Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016

2016-11-15 06:13:25 | ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an

2016-11-14 17:53:33 | ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report

2016-11-14 16:17:12 | Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results

2016-11-14 07:07:04 | Q3 2016 Acura Pharmaceuticals Inc Earnings Release - After Market Close

2016-11-09 10:39:08 | Acura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15, 2016

2016-11-09 10:30:00 | Acura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15, 2016

2016-10-18 09:36:12 | ETF’s with exposure to Acura Pharmaceuticals, Inc. : October 18, 2016